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Abstract
Objective Our objective was to estimate 4-year health-
care costs associated with the metabolic profile of patients
before and after 1 year of treatment with phentermine
(15 mg) and topiramate extended-release (92 mg) [phen-
termine-topiramate ER].
Design and Methods Using a medical records database,
we created two patient cohorts reflecting metabolic profiles
of subjects before and after phentermine-topiramate ER
therapy during the 1-year CONQUER trial. We matched
database patients with trial subjects by age, sex, body mass
index (BMI), and hypertension, glycemic, and triglyceride
status. We collected real-world data on emergency de-
partment and outpatient visits, hospitalizations, and drug
prescriptions over 4 years, linking them to reimbursements
to estimate US private insurance costs for post-trial
(n = 2295) versus pre-trial intention-to-treat (ITT) patients
(n = 2295). Secondary analysis assessed responders
(completers losing C5 % body weight [n = 1285]).
Results Over 4 years, the mean cost per patient in the
post- versus pre-trial ITT-group was $US32,432 versus
$US34,725 (mean difference -2292; 95 % confidence in-
terval [CI] –4776 to 209). In responders, corresponding
costs were $US30,558 versus $US33,936 (mean difference
–3378; 95 % CI –6496 to –464). Costs for post- versus pre-
trial responders were lower for outpatient visits, emergency
visits, and medications (all P\ 0.05).
Conclusion Excluding treatment cost and potential side
effects, patients matched to profiles of phentermine-topi-
ramate ER responders had lower costs than patients mat-
ched to pre-treatment profiles.
Key Points
During recent decades, worldwide obesity has
increased. The estimated number of obese
individuals exceeded 0.5 billion in 2008 (7 % of the
global population) and currently, 70 % of US adults
are either overweight or obese
Obesity is associated with multiple comorbidities,
and obese patients incur higher healthcare costs than
do non-obese patients
In this study, which matched metabolic profiles
before and after drug treatment with those of real-
world patients, weight loss of the magnitude
achieved in clinical trials with phentermine-
topiramate extended-release resulted in lower
healthcare costs for responders over 4 years
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1 Introduction
Despite public health targets for obesity reduction, the
proportion of obese US adults was estimated at 35 % in
2012 [1]. Compared with normal weight individuals, obe-
sity is associated with increased all-cause mortality, pri-
marily due to a strong association with cardiovascular
deaths [2–5]. Obesity is also associated with multiple co-
morbidities, including type 2 diabetes mellitus (T2DM),
cardiovascular disease, cancer, asthma, gallbladder disease,
osteoarthritis, hyperlipidemia, and chronic back pain [6–9].
Obese individuals have increased comorbidities; there-
fore, medical costs for these people are significantly higher
than those for normal weight individuals [10, 11]. Fur-
thermore, the cost differential rises as obesity worsens.
Two independent observational US database studies re-
ported cost increases of 25 % for class I obese individuals
(body mass index [BMI] 30–34.9 kg/m2) and 50 % for
class II obese individuals (BMI 35–40 kg/m2) compared
with normal weight individuals [11, 12]. Increases were
observed in both inpatient and outpatient categories of
service and were also independently observed in costs and
numbers of prescriptions [11, 13]. Data from the US Health
and Retirement Study demonstrated a mean increase in
medical costs of $US1829 per year (year 2012 values) for
obese compared with normal weight individuals [11].
In 2012, the US FDA approved a combination of
phentermine and topiramate extended-release (ER) for
chronic weight management with lifestyle modification in
patients with obesity-related comorbidities. In intention-to-
treat (ITT) analysis, this combination led to a C10 %
weight loss at 1 year in 48 % of patients receiving daily
phentermine (15.0 mg) and topiramate ER (92.0 mg) and
37 % of patients receiving daily phentermine (7.5 mg) and
topiramate ER (46.0 mg) compared with 7 % in the
placebo group [14]. In an extension trial that followed a
subgroup of patients who continued the medication, weight
loss was sustained at 2 years [15].
Few clinical trials of anti-obesity drugs have included an
explicit economic component despite growing concern
about the cost of new treatments. In the absence of trial
data, most studies of the cost impacts of anti-obesity drugs
have employed modeling approaches based on assumptions
of weight loss maintenance and a linear relationship be-
tween BMI status and costs [16]. A recently published
analysis of phentermine-topiramate ER imputed direct
medical cost reductions using 1-year patient-reported
medication changes during the clinical trial along with
assumptions about physician visits, reporting an incre-
mental cost-effectiveness ratio of $US48,000 per quality-
adjusted life-year (QALY) over a 3-year time horizon [17].
We aimed to estimate the change in medical services and
costs associated with the metabolic improvements achieved
with phentermine-topiramate ER treatment by matching
real-world patients to the metabolic profiles of subjects
post- and pre-treatment from the CONQUER trial. How-
ever, instead of using assumptions about the impact of BMI




The primary analysis evaluated patient cohorts modeled on
ITT subjects in the phentermine (15 mg) and topiramate
ER (92 mg) [phentermine-topiramate ER] study arm of the
randomized controlled CONQUER trial [14]. A secondary
analysis modeled ‘responder’ subjects completing the
CONQUER trial on phentermine-topiramate ER. Similar to
previous work on orlistat and sibutramine [16], ‘respon-
ders’ represented the subgroup of subjects who remained
on therapy and lost C5 % of their body weight by the end
of the CONQUER trial.
CONQUER ITT phentermine-topiramate subjects were
characterized by sex, age, and inclusion criteria (BMI,
glucose status, blood pressure, and triglyceride level) at the
beginning (pre-trial) and end (post-trial) of the 1-year
CONQUER study. Missing data were handled using last
observation carried forward, consistent with the original
publication [14].
A set of de-identified Health Insurance Portability and
Accountability Act of 1996 (HIPAA)-compliant medical
records of patients aged C40 years having at least two
values for BMI between 2007 and 2011 was obtained from
Humedica, Inc. (Cambridge, MA, USA; n = 1.49 million).
Though younger subjects represented 15 % of ITT subjects
in the CONQUER study arm we modeled, records for pa-
tients under 40 years were not available for release. An
index date was assigned to each patient’s first encounter
that included a valid BMI preceded by C6 months of
clinical data. For inclusion, patients were required to
have C3 years of follow-up data from the index date.
Next, CONQUER clinical exclusion criteria were ap-
plied to the database patients. Remaining patients were
classified by sex, age, BMI, hypertension status, glycemic
status, and triglyceride status on their index dates. To de-
velop patient cohorts, up to three patients from the re-
maining pool of eligible database patients were matched
(with replacement) to each CONQUER subject’s post-trial
and pre-trial states using the following six criteria: age
(±3 years), sex, BMI (±1 kg/m2), hypertension status,
glycemic status (normal, prediabetes, or diabetes), and
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hypertriglyceridemia status (for further details, see the
Electronic Supplementary Material [ESM] 1, Figure S1).
Hypertension was defined as diastolic blood pres-
sure C90 mmHg (C85 mmHg with T2DM), systolic blood
pressure C140 mmHg (C130 mmHg with T2DM), use of
any anti-hypertensive medication, or a diagnosis code
indicating hypertension. T2DM was defined as glycosy-
lated hemoglobin (HbA1c) C6.5 %, fasting glucose C126
mg/dL, use of any anti-diabetic medication, or a diagnosis
code indicating T2DM. Prediabetes (in patients without
T2DM) was defined as HbA1c 5.7–6.4 %, fasting glucose
100–125 mg/dL, or a diagnosis code indicating pre-
diabetes. Hypertriglyceridemia was defined as C200 mg/
dL or two or more lipid-lowering medications.
2.2 Utilization and Costs
For each database patient included in the matched study
population, tabulations were made of inpatient, outpatient,
and emergency department visits; lab tests; and written
prescriptions for up to 4 years following the patient’s index
date. Outpatient visits were defined as encounters that in-
cluded a physical observation, diagnosis code, or a proce-
dure other than specimen collection or lab testing on a day
that did not include inpatient or emergency department
care. We counted all outpatient care received by a patient
on 1 day as a single outpatient visit.
Written prescriptions were categorized by generic name
without regard to dose. That is, all doses of a specific
medication were considered to be the same medication.
Combination pharmaceuticals were classified according to
major or first-listed ingredient, with the exception of ac-
etaminophen/codeine and acetaminophen/oxycodone.
When the number of refills was not specified, we used the
mean number of refills for the specific medication calcu-
lated from the overall dataset. For medications without
mean refill data, we used the mean number of refills of that
medication’s class or, in rare instances, the mean number
of refills of all medications in the dataset.
To assess US private insurer costs, data from OptumIn-
sight (Minneapolis, MN, USA) were obtained on calendar
year 2011 private insurance plan costs for inpatient stays by
diagnosis-related group (DRG), outpatient visits by type,
and emergency department visits, along with 139 of the
most common prescription drugs (representing 75 % of all
prescriptions in the study period) and the 34 most common
laboratory tests (representing 73 % of all tests). Cost is
presented from a private insurance plan perspective.
Throughout, the terms ‘cost’ and ‘costs’ refer to insurance-
allowed reimbursements, defined as the amount payable
after discounts but prior to application of any deductible,
copay, co-insurance, or coordination of benefits.
Cost for each hospital inpatient stay was estimated us-
ing length of stay, DRG-specific cost per day, and the
mean physician cost per inpatient day (details in ESM 1).
For encounters or services that were identified in the data
but could not be classified (e.g., an inpatient stay with no
diagnosis code or a prescription with no medication name),
we applied the weighted mean cost of that type of service
from the overall dataset. Though the costs of laboratory
tests were included in outpatient encounter costs, outpa-
tient laboratory utilization was assessed separately from
other outpatient encounters to avoid skewing utilization
totals.
2.3 Follow-Up
Healthcare utilization and costs were evaluated in pa-
tients matched to the CONQUER pre-trial and post-trial
subjects for up to 4 years after a patient’s index date,
with no requirement with respect to weight maintenance,
loss, or gain or any other metabolic changes. At the time
of this analysis, long-term patient adherence, treatment
efficacy, and safety of phentermine-topiramate are not
known. Accordingly, our methodology did not exclude
patients who gained weight during the 4 years of follow-
up, nor did we attempt to adjust the outcomes to account
for the possibility of weight rebound or further weight
loss.
The non-discounted cost of phentermine-topiramate ER
treatment, currently $US2868 per year [18, 19], was not
incorporated into the analysis.
2.4 Statistical Methods
P values and 95 % confidence intervals (CIs) for the dif-
ferences in means were calculated using non-parametric
bootstrapping to avoid distributional assumptions. Ana-
lyses were carried out with SAS version 9.2.
3 Results
3.1 Patient Characteristics
Mean BMI was 32 kg/m2 among patients matched to the
post-trial state of CONQUER ITT subjects compared with
a mean BMI of 36 kg/m2 among patients matched to the
pre-trial state of such subjects. Among responders, con-
stituting 56 % of the sample (1289/2295), the mean BMI
comparison between post- versus pre-trial groups was 31
versus 36 kg/m2. Demographic characteristics of the pa-
tients matched to CONQUER subjects are listed in
Table 1.
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3.2 Health Resources Utilization
3.2.1 Primary Analysis
Patients matched to post-trial CONQUER ITT subjects
sought fewer services during the 4-year study period than
did patients matched to pre-trial CONQUER ITT subjects
(Fig. 1). Patients matched to post-trial CONQUER ITT
subjects (Fig. 1a) had fewer outpatient visits (39 vs. 42;
mean difference –3; 95 % CI –5 to –2; P\ 0.001) and
received fewer prescriptions (40 vs. 45; mean difference
–5; 95 % CI –7 to –3; P\ 0.001) than patients matched to
pre-trial CONQUER ITT subjects. No differences were
observed between the post- and pre-trial matching groups
for inpatient admissions (0.43 vs. 0.46; mean difference
–0.03; 95 % CI –0.10 to 0.04; P = 0.44) or emergency
department visits (0.9 vs. 1.0; mean difference –0.1; 95 %
CI –0.30 to –0.02; P = 0.08).
3.2.2 Secondary Analysis (Responders)
Patients matched to post-trial responder subjects (Fig. 1b)
had fewer outpatient visits (37 vs. 41; mean difference –4;
95 %CI –2 to –6;P\ 0.001), fewer prescriptions (37 vs. 45;
mean difference –8; 95 % CI –11 to –6; P\ 0.001), and
fewer emergency department visits (0.8 vs. 1.1; mean dif-
ference –0.3; 95 % CI –0.5 to –0.1; P\ 0.01) than patients
matched to pre-trial responder subjects. No difference was
observed for inpatient admissions (0.40 vs. 0.45; mean dif-
ference –0.05; 95 % CI -0.15 to 0.04; P = 0.26).
3.3 Healthcare Costs
3.3.1 Primary Analysis
Over 4 years, mean per-patient costs for patients matched
to post- versus pre-trial CONQUER ITT subjects were
$US32,432 and $US34,725 (mean difference –2292; 95 %
CI –4776 to 209; P = 0.08). While this overall difference
did not reach statistical significance, patients matched to
post- versus pre-trial CONQUER subjects had significantly
lower outpatient costs ($US16,901 vs. $US18,035; mean
difference –1134, 95 % CI –2122 to –110; P = 0.03) and
lower total prescription costs ($US7271 vs. $US8331;
mean difference –1060; 95 % CI –1553 to –558;
P\ 0.001; Fig. 2). Lower prescription costs were reflected





Model set Pre-trial Post-trial P value Pre-trial Post-trial P value
N 2295 2295 1289 1289
Mean age in years (SD) 54 (8) 55 (8) 54 (8) 55 (8)
Women, n (%) 1613 (70) 1613 (70) 905 (70) 905 (70)
BMI (kg/mb), mean (SD) 36 (4) 32 (5) <.0001 36 (4) 31 (4) <.0001
Type 2 diabetesa, n (%) 475 (21) 428 (19)
0.17
229 (18) 155 (12)
<.0001
Prediabetesb, n (%) 1182 (52) 1192 (52) 711 (55) 708 (55)
Hypertensionc, n (%) 1786 (78) 1620 (71) <.0001 1023 (79) 888 (69) <.0001
Elevated triglyceridesd, n 
(%) 
571 (25) 289 (13) <.0001 349 (27) 139 (11) <.0001
Data are presented as n (%) unless otherwise indicated
BMI body mass index, HbA1c glycosylated hemoglobin, ITT intent-to-treat population, SD standard deviation, T2DM type 2 diabetes mellitus
a T2DM (any criterion): HbA1c C6.5 %; fasting glucose C126 mg/dL; any anti-diabetes medication; diagnosis codes indicating T2DM
b Prediabetes (in patients without diabetes, any criterion): HbA1c 5.7 %–6.4 %; fasting glucose 100–125 mg/dL; diagnoses codes indicating
prediabetes
c Hypertension (any criterion): diastolic blood pressure C90 (C85 with T2DM); systolic blood pressure C140 (C130 with T2DM); any anti-
hypertensive medication; diagnosis codes indicating hypertension
d Hypertriglyceridemia: C200 mg/dL or more than one lipid-lowering drug
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in all medication groups as well as specifically in three
categories of medications commonly used to treat obesity-
related comorbidities (Fig. 3).
No differences between the post- and pre-trial groups
were observed in inpatient costs ($US7068 vs. $US6974;
mean difference 95; 95 % CI –1632 to 1895; P = 0.91) or
emergency department costs ($US1192 vs. $US1385; mean
difference –193; 95 % CI –405 to 2; P = 0.07).
3.3.2 Secondary Analysis (Responders)
In the secondary analysis of responders, mean costs in
patients matched to post- versus pre-trial subjects were
$US30,558 and $US33,936 (mean difference –3378; 95 %
CI –6496 to –464; P = 0.03). In subgroup analysis, pa-
tients matched to post- versus pre-trial subjects had sig-
nificantly lower outpatient costs ($US16,099 vs.
 $6,974  $7,068
 $1,385  $1,192
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Fig. 1 Mean per-patient utilization of outpatient visits, inpatient admissions, and emergency department visits, and mean number of
prescriptions written during study period. P values estimated using nonparametric bootstrapping. ITT intention-to-treat
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$US17,644; mean difference –1545; 95 % CI –2800 to
–208; P = 0.02), lower prescription costs ($US6598 vs.
$US8216; mean difference –1618; 95 % CI –2216 to
–1002; P\ 0.001), and lower emergency department costs
($US1019 vs. $US1418; mean difference –399; 95 % CI
–639 to –143; P\ 0.001). No difference between the post-
and pre-trial responder groups was observed in inpatient
costs ($US6842 vs. $US6659; mean difference 184; 95 %
CI –1986 to 2096; P = 0.86).
4 Discussion
4.1 Main Findings
We studied healthcare cost trajectories over 4 years in
patient groups with metabolic profiles reflecting the post-
trial and pre-trial characteristics of patients receiving
12 months of phentermine-topiramate ER treatment. Ex-
cluding phentermine-topiramate ER costs, we found no
statistically significant difference in costs overall among
the ITT-matched group, but did observe cost savings
for responders (patients matched to study completers los-
ing C5 % of initial weight). The bulk of estimated savings
(94 %) originated from lower prescription medication costs
as well as emergency department and outpatient visit costs.
4.2 Previous Research
Several cost-effectiveness analyses have been published for
the anti-obesity drugs orlistat, sibutramine, and rimonabant
[16]. These analyses have generally modeled costs over the
long term based on assumptions regarding weight loss main-
tenance and a linear relationship between BMI status and
costs. When the weight loss drug cost was included, none of
these modeling studies found drug treatment to be cost saving
compared with standard care. Nevertheless, most found the
drugs tobewithin the boundaries ofwhat is generally regarded
as cost effective. Themajority of the studies used a treatment-
responder approach, where patients not losing[5 % of initial
weight after 3 months were taken off drug. A recent study
modeled the cost effectiveness of Qsymia versus diet and
lifestyle using 1-year self-reported healthcare utilization and
quality-of-life data and assumptions regardingmaintenance of
effects over an additional 2 years [17]. The study found
Qsymia to be associated with an incremental cost-effective-
ness ratio of $US48,000 per QALY, but that the result was
sensitive to assumptions regarding extrapolation of effects
beyond the first year. The study did not investigate cost ef-
fectiveness according to the treatment-responder approach
recommended for clinical use of the drug.
Our cost analysis entailed a design that identified actual
patients in a US database matched to pre- and post-trial
patient characteristics. Excluding intervention costs, we
analyzed costs for all patients as well as for the subset of
treatment responders defined as C5 % weight loss at
12 months. Our design does not allow direct comparisons
with the modeled costs in previous cost-effectiveness
analyses. However, given that the 12-month placebo-ad-
justed weight loss for phentermine-topiramate ER was
approximately 9 kg (compared with\5 kg for sibutramine
and rimonabant and\3 kg for orlistat) [14, 20], one would






























































Fig. 3 Mean cost of prescriptions for diabetes, hypertension, and elevated lipids during 4-year study period. P values estimated using
nonparametric bootstrapping. ITT intention-to-treat
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4.3 Mechanisms
Voluntary weight loss and accompanying improvements
in metabolic risk factors may result in lower drug use and
reduced healthcare needs through several mechanisms,
including better glycemic control and prevention of car-
diovascular events. Bariatric surgery, which results in
substantial and sustained weight loss, has been shown
both to prevent T2DM in non-diabetic patients [21] and to
induce remission of disease [22, 23]. Also, lower inci-
dences of stroke and myocardial infarction have been
reported [24]. However, over up to 20 years of follow-up,
healthcare use was similar or higher in the surgery group
than in the control group in the Swedish Obese Subjects
study, while prescription costs were lower [25].
Drug-induced weight loss is of lower magnitude than
surgery-induced weight loss and has not been shown to be
as sustainable [20, 26]. Still, randomized placebo-con-
trolled trials of both orlistat and phentermine-topiramate
ER have shown lower incidence of T2DM over 4 and
2 years, respectively [27, 28]. This is likely to translate into
lower costs for medication and clinical follow-up of dia-
betes. In our analysis over 4 years, we found lower costs
for anti-diabetes drugs in the post- vs. pre-trial ITT group
(P = 0.04).
Regarding cardiovascular events, no data exist for
orlistat or phentermine-topiramate ER, although both drugs
have beneficial short-term effects on intermediate measures
such as lipids and blood pressure [14, 20]. In the only
completed randomized trial to date of a weight-loss drug
with cardiovascular events as primary outcome, a small but
statistically significantly higher risk was observed in si-
butramine-treated patients than in those receiving placebo,
leading to withdrawal of market authorization [29]. Ri-
monabant was also tested for prevention of cardiovascular
events in a study enrolling more than 18,000 patients, but
the trial was terminated prematurely due to neuropsychi-
atric effects [30].
In contrast to both orlistat and phentermine-topiramate
ER, sibutramine has been shown to be associated with in-
creases in blood pressure compared with placebo [14, 31].
However, like sibutramine, phentermine-topiramate ER has
been reported to raise heart rate, although the clinical im-
portance of this finding is currently unclear [32]. Concerns
about potential adverse events, including cardiovascular
events, resulted in the European Medicines Agency (EMA)
rejecting the market application for phentermine-topira-
mate ER [33]. Long-term cardiovascular outcomes of
phentermine-topiramate ER are being investigated in the
AQCLAIM (A Qsymia Cardiovascular morbidity and
Mortality) study, in accordance with post-marketing re-
quirements of the FDA (ClinicalTrials.gov; EudraCT
Number 2012-003946-34).
4.4 Strengths
Our cost analysis used a different approach to estimate costs
over 4 years than prior cost-effectiveness analyses of
weight-loss drugs [16]. Instead of assuming a linear rela-
tionship between BMI, body weight, or weight loss on the
one hand and costs on the other, we matched real-world
patients to six metabolic and demographic parameters of
CONQUER trial patients before and after phentermine-
topiramate ER treatment and observed actual medical ser-
vice utilization and costs over 4 years. These cost estimates,
based on observed resource use between 2007 and 2011 and
average per-service costs for insured US patients in 2011,
are likely more generalizable to the US setting than esti-
mates from hypothetical cohorts of patients and modeled
costs generated by other cost-effectiveness models.
4.5 Limitations
This study is an examination of resource use and related
costs in patients with characteristics mirroring the charac-
teristics of patients before and after 12 months of phen-
termine-topiramate ER treatment. Since 4-year follow-up
data on patients taking phentermine-topiramate ER are
unavailable, we were unable to assess the extent to which
changes in weight and metabolic markers in the patients
whose natural history we followed could differ from results
in actual phentermine-topiramate ER patients over a
similar period. Therefore, the results need to be validated,
preferably in both observational and randomized inter-
vention studies.
As we did not observe actual phentermine-topiramate
ER-treated patients, we also did not include costs for po-
tential short- or long-term adverse events. Both sibutramine
(USA and Europe) and rimonabant (Europe) were with-
drawn from the market because of their adverse event
profile after initially being approved. The safety of phen-
termine-topiramate ER beyond 2 years is currently un-
known [15]. We also did not include phentermine-
topiramate ER drug costs, which would require us to make
assumptions regarding duration of treatment, compliance,
and weight development over the 4 years of follow-up.
The patient groups we created did not fully reflect pa-
tients in the CONQUER trial. Specifically, we only had
access to patients aged C40 years, representing 85 % of
CONQUER ITT subjects in the modeled study arm; we did
not match on race or smoking history because a large
number of database records lacked these; we did not have
information on mortality or direct information on when
patients may have transferred their care to another provider
system; and we did not have a full 4 years of follow-up
data for all patients. However, these limitations applied to
both the pre- and the post-trial patient groups.
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5 Conclusion
In this database study, which explored the potential 4-year
cost effects of metabolic improvements observed over
12 months of phentermine-topiramate ER treatment, we de-
tected some health resource utilization differences, but no
statistically significant overall cost differences between pa-
tients representing post- versus pre-trial metabolic profiles in
the ITT analysis. When restricting our analysis to patients
losing C5 % of initial body weight, the threshold used in
some countries for continuing weight-loss drug treatment and
the threshold used by the manufacturer in its instructions to
patients [16, 32], cost savings of about $US3400 were ob-
served over 4 years, reflecting reduced utilization of all
measured categories of medical services except inpatient
admissions. Future analyses should factor in costs related to
treatment of adverse events and compliance-based costs of the
treatment itself. We recommend validation of these findings
in observational and randomized intervention studies.
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